


**IN THE CLAIMS**

Please amend claims 67 and 91, as shown below. Please add new claim 95. The following listing of claims replaces all prior listings.

1-66. (Canceled).

67. (Currently amended) A method for the treatment of a mitochondrial disorder comprising administering to a subject having or at risk of having such disorder an effective amount of a compound having the general Formula I:



(I)

wherein the mitochondrial disorder is selected from a group consisting of mitochondrial renal tubular acidosis, multiple mitochondrial deletion syndrome, Leigh syndrome, lactic acidemia, 3-hydroxybutyric acidemia, encephalomyopathy, 1+proteinuria, pyruvate dehydrogenase deficiency, complex I deficiency, complex IV deficiency, aminoaciduria, hydroxyprolinuria, ataxia, and MARIAHS syndrome, and wherein the compound is selected from uridine and 1- $\beta$ -D-ribofuranosyluracil.

68-69. (Canceled).

70. (Previously presented) The method according to claim 67, wherein the mitochondrial disorder is a primary disorder comprising at least one mutation in mitochondrial or nuclear DNA.

71-72. (Canceled)

73. (Previously presented) The method according to claim 67, wherein said mitochondrial disorder is a secondary disorder caused by acquired somatic mutations, physiologic effects of drugs, viruses, or environmental toxins that inhibit mitochondrial function.

74. (Previously presented) The method according to claim 67, wherein the mitochondrial disorder is a deficiency of cardiolipin.

75. (Previously presented) The method according to claim 67, wherein the mitochondrial disorder comprises a deficiency in a pyrimidine synthetic pathway.

76. (Previously presented) The method according to claim 74, wherein the deficiency in a pyrimidine synthetic pathway is the uridine synthetic pathway.

77. (Previously presented) The method according to claim 74, wherein the deficiency comprises reduced expression and/or activity of an enzyme in the pyrimidine synthetic pathway.

78. (Previously presented) The method according to claim 77, wherein the enzyme is selected from the group consisting of dihydroorotate dehydrogenase (DHOD) and uridine monophosphate synthetase (UMPS).

79. (Previously presented) The method according to claim 67, wherein the mitochondrial disorder results in lower than normal uridine levels.

80. (Previously presented) The method according to claim 67, wherein the mitochondrial disorder is the result of prior or concurrent administration of a pharmaceutical agent.

81. (Previously presented) The method according to claim 80, wherein the pharmaceutical agent is a reverse transcriptase inhibitor, a protease inhibitor or an inhibitor of DHOD.

82. (Previously presented) The method according to claim 81, wherein the reverse transcriptase inhibitor is Azidothymidine (AZT), Stavudine (D4T), Zalcitabine (ddC), Didanosine (DDI) or Fluoroiodoarauracil (FIAU).

83. (Previously presented) The method according to claim 81, wherein the protease inhibitor is Ritonavir, Indinavir, Saquinavir or Nelfinavir.

84. (Previously presented) The method according to claim 81, wherein the DHOD inhibitor is Leflunomide or Brequinar.

85. (Previously presented) The method according to claim 67, further comprising the administration of one or more co-factors, vitamins, or mixtures of two or more thereof.

86. (Previously presented) The method according to claim 85, wherein the co-factor is one or both of Coenzyme Q10 or calcium or magnesium pyruvate.


87. (Previously presented) The method according to claim 85, wherein the vitamin is selected from the group consisting of thiamine (B1), riboflavin (B2), niacin (B3), pyridoxine (B6), folate, cyanocobalamin (B12), biotin,  $\alpha$ -lipoic acid, and pantothenic acid.

88. (Previously presented) The method according to claim 67, wherein the compound of Formula (I) is administered in a daily dosage in the range of about 0.5 g/m<sup>2</sup> to 20 g/m<sup>2</sup>.

89. (Previously presented) The method according to claim 67, wherein the compound of Formula (I) is administered in a daily dosage in the range of about 2 g/m<sup>2</sup> to 10 g/m<sup>2</sup>.

90. (Previously presented) The method according to claim 67, wherein the compound of Formula (I) is administered in a daily dosage of about 6.0 g/m<sup>2</sup>.

91. (Currently amended) A method for reducing or eliminating one or more symptoms associated with a mitochondrial disorder comprising administering to a subject in need thereof an effective amount of a compound having the general Formula (I):



(I)

wherein the mitochondrial disorder is selected from a group consisting of mitochondrial renal tubular acidosis, multiple mitochondrial deletion syndrome, Leigh syndrome, lactic acidemia, 3-hydroxybutyric acidemia, encephalomyopathy, 1+proteinuria, pyruvate dehydrogenase deficiency, complex I deficiency, complex IV deficiency, aminoaciduria, hydroxyprolinuria, ataxia, and MARIAHS syndrome, and wherein the compound is selected from uridine and 1-β-D-ribofuranosyluracil.

In the Application of  
Robert K. Naviaux  
Application Serial No.: 09/889,251  
Filed: November 1, 2001  
Page 6

PATENT  
Attorney Docket No.: UCSD1140-1

92-94. (Canceled).

95. (New). The method according to any one of claims 67 or 91, wherein the mitochondrial disorder is MARIAHS syndrome.